Alkem Laboratories has been awarded a ‘Certificate of GMP Compliance of a Manufacturer’ by the Malta Medicines Authority for its manufacturing facility located in Daman, India. This certification is valid for a period of three years from the date of inspection, which was conducted on 9th December 2025.
The certification confirms that Alkem’s Daman facility complies with the Good Manufacturing Practice (GMP) standards required by the European Union. This recognition is crucial for the company as it allows the facility to manufacture and export pharmaceutical products to EU countries, ensuring that the products meet the stringent quality standards expected by the European market.
Alkem Laboratories had previously notified the National Stock Exchange of India (NSE) about the GMP inspection by the Malta Medicines Authority in December 2025. The receipt of this certificate marks a significant milestone for the company, reinforcing its commitment to maintaining high-quality manufacturing standards.
The company has made this disclosure available on its website in compliance with Regulation 30(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).